Seaport Therapeutics 3Q 2026: Net loss $26.4M, diluted loss per share $0.49— 10-Q Summary
Seaport Therapeutics reported a net loss of $26.4M in Q3 2026, up $3.9M from the prior year. Diluted loss per share was $0.49, compared to $9.43, due to a higher share count. The company is advancing its pipeline, with key trials expected to report results in 2027 and 2028, and anticipates continued operating losses.
How this was made
The 30-second read
Why it matters
The Q3 loss highlights ongoing cash burn without near‑term revenue, underscoring financing risk.
Market read
Quarterly loss disclosure provides fresh data for traders evaluating exposure to early‑stage biotech stocks.
What to watch
Phase 2b BUOY‑1 results expected early 2027 could mitigate concerns if data are positive.
Background
Seaport Therapeutics is a clinical‑stage biotech focusing on neuropsychiatric disorders.
Ticker impact
Seaport Therapeutics filed its 10‑Q reporting a Q3 2026 net loss of $26.4 M, a widening versus the prior year.
likely downward pressure as the market prices in higher losses
Quarterly loss numbers are new primary disclosure; loss widened and no revenue guidance was provided.
Market effects
Biotech sector may see modest risk‑off as cash‑burn concerns persist.
US small‑cap biotech investors could adjust exposure.
Limited to niche biotech investors.
Counterpoint
If the pipeline advances successfully, the loss may be viewed as a temporary investment in future growth.
Key entities
- companySeaport Therapeutics
Biotech firm reporting Q3 2026 results.